Local and Systemic Complications after Intravitreal Administration of Anti-Vascular Endothelial Growth Factor Agents in the Treatment of Different Ocular Diseases: A Five-Year Retrospective Study

Nuzzi, Raffaele; Tridico, F

doi:10.3109/08820538.2013.835833

Cited by 30 publications

(27 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There were five RCTs1920212223 and 17 non-RCT studies1415161724252627282930313233343536. The latter group included 11 retrospective case series1417242526272829303132, two prospective studies3334, and four post hoc analyses15163536. Follow-up in the included articles ranged from 2.2627 to 6031 months.…”

Section: Resultsmentioning

confidence: 99%

“…The latter group included 11 retrospective case series1417242526272829303132, two prospective studies3334, and four post hoc analyses15163536. Follow-up in the included articles ranged from 2.2627 to 6031 months. Detailed characteristics of comparative and non-comparative studies are provided in Table 1 and Table 2, respectively.…”

Section: Resultsmentioning

confidence: 99%

“…Eleven retrospective1417242526272829303132 and two prospective3334 studies, which reported the case numbers and incidence rates of SE-IOP among the 5062 subjects, were analyzed. Prevalence of SE-IOP varied from 1.6% (5 of 302 cases) to 11% (22 of 201 case), with a pooled prevalence (Fig.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Sustained Elevation of Intraocular Pressure Associated with Intravitreal Administration of Anti-vascular Endothelial Growth Factor: A Systematic Review and Meta-Analysis

Zhou

Xia

et al. 2016

Sci Rep

View full text Add to dashboard Cite

This study aimed to assess whether repetitive intravitreal injections (IVI) of anti-vascular endothelial growth factor (anti-VEGF) cause sustained elevation of intraocular pressure (SE-IOP). We conducted a systematic review and meta-analysis based on five randomized controlled trials (RCTs) assessing 1428 subjects and 17 non-RCTs evaluating 8358 cases. In the RCTs, an increased risk of SE-IOP was found in the anti-VEGF group (summary risk ratio [RR] = 3.00, 95% confidence interval [CI]: 1.63–5.53) compared with the sham injection or laser group. The increased risk of SE-IOP was correlated with follow-up duration (RR = 2.14, 95% CI 0.69–6.57 at 6 months; RR = 3.15, 95% CI 0.99–10.09 at 12 months; RR = 3.48, 95% CI 1.38–8.78 at 23 months). The risk of SE-IOP after non-exclusion of pre-existing glaucoma patients (RR = 3.48, 95% CI 1.38–8.78) was higher than that obtained after excluding pre-existing glaucoma patients (RR = 2.6, 95% CI 1.16–5.81). In non-RCTs, the pooled prevalence of SE-IOP was 4.7% (95% CI 3.7–5.8) regardless of diagnosis criteria. In conclusion, repeated intravitreal injections of anti-VEGF agents cause a 2-fold elevation in SE-IOP risk.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Sustained Elevation of Intraocular Pressure Associated with Intravitreal Administration of Anti-vascular Endothelial Growth Factor: A Systematic Review and Meta-Analysis

Zhou

Xia

et al. 2016

Sci Rep

View full text Add to dashboard Cite

show abstract

“…An inflammatory response after an intravitreal injection is a rare complication [8]. In the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) study, four out of a total of 1,185 study participant had uveitis following the injection.…”

Section: Discussionmentioning

confidence: 99%

“…Noninfectious inflammatory reactions have been documented for ranibizumab (Lucentis TM ), bevacizumab (Avastin TM ), and aflibercept (Eylea TM ). Many of the theories for the causes of untoward side effects involve an immune reaction to the drug itself or to possible impurities gathered in the manufacture, storage, or preparation of the agent [8]. …”

Section: Introductionmentioning

confidence: 99%

Noninfectious Inflammatory Response following Intravitreal Bevacizumab Injections: Description of a Cluster of Cases in Two Centers and a Review of the Literature

et al. 2018

View full text Add to dashboard Cite

Purpose: To report a cluster of high incidence of noninfectious inflammatory reaction shortly after bevacizumab injection. Methods: Data were collected from medical records of consecutive patients who underwent bevacizumab injections and presented with acute uveitis within 1–4 days. Results: All 7 patients were injected intravitreally with bevacizumab from different batches and presented with visual deterioration. One patient with anterior uveitis complained of pain. None had hypopyon. Three patients with vitritis underwent a vitreous tap with an intravitreal injection of vancomycin and ceftazidime for possible infectious endophthalmitis. All patients received intensive topical antibiotic drops and steroids, and the intraocular inflammation resolved completely within 1 month. Five patients continued to receive bevacizumab injections without recurrent episodes. Conclusions: Our series demonstrates an incidence of noninfectious inflammatory reaction shortly after bevacizumab injection that is higher than that reported in the literature. The cause is more likely the preparation process in the same compounding pharmacy.

show abstract

VEGF inhibition alters neurotrophin signalling pathways and induces caspase‐3 activation and autophagy in rabbit retina

Segatto

Fico

Gharbiya

et al. 2019

Journal Cellular Physiology

View full text Add to dashboard Cite

This study sought to evaluate the prospective role exerted by vascular endothelial growth factor (VEGF) in the modulation of nerve growth factor (NGF) and brain‐derived neurotrophic factor (BDNF) signalling pathways in the rabbit retina. To reach this aim, the anti‐VEGF agents aflibercept and ranibizumab were used as a pharmacological approach to evaluate the putative consequences elicited by VEGF inhibition on neurotrophin signalling. VEGF inhibition determined a marked imbalance in proneurotrophin expression, a significant reduction in TrkA and TrkB phosphorylation states and a decrease in the pan‐neurotrophin receptor p75. Importantly, VEGF blockade also caused a strong increase in cleaved caspase‐3, beclin‐1 and lipidated LC3. The effects were more pronounced in the aflibercept group when compared with ranibizumab‐treated rabbits, particularly 1 week after injection. This study demonstrates that VEGF exerts pivotal physiological roles in regulating NGF and BDNF pathways in the retina, as its inhibition by anti‐VEGF agents deeply impacts neurotrophin homeostasis. These events are accompanied by a sustained induction of apoptotic and autophagic markers, suggesting that anti‐VEGF‐dependent impairments in neurotrophin signalling could be responsible for the activation of retinal cell death pathways.

show abstract

Local and Systemic Complications after Intravitreal Administration of Anti-Vascular Endothelial Growth Factor Agents in the Treatment of Different Ocular Diseases: A Five-Year Retrospective Study

Cited by 30 publications

References 32 publications

Sustained Elevation of Intraocular Pressure Associated with Intravitreal Administration of Anti-vascular Endothelial Growth Factor: A Systematic Review and Meta-Analysis

Sustained Elevation of Intraocular Pressure Associated with Intravitreal Administration of Anti-vascular Endothelial Growth Factor: A Systematic Review and Meta-Analysis

Noninfectious Inflammatory Response following Intravitreal Bevacizumab Injections: Description of a Cluster of Cases in Two Centers and a Review of the Literature

VEGF inhibition alters neurotrophin signalling pathways and induces caspase‐3 activation and autophagy in rabbit retina

Contact Info

Product

Resources

About